Company: DHR
Filing Date: 2025-03-26
Form Type: DEF 14A
Source: 0000313616-25-000081
Chunk: 33

Company: DANAHER CORP /DE/
Filing Date: 2025-03-26
Form: DEF 14A
Chunk 33
---
 in the best interests of Danaher and its shareholders.

In fulfilling its responsibilities, the Audit Committee has reviewed and discussed with Danaher’s management and Ernst & Young Danaher’s audited consolidated financial statements and internal control over financial reporting.

The Audit Committee has discussed with Ernst & Young those matters required to be discussed under the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the SEC. In addition, the Audit Committee has received the written disclosures and the letter from Ernst & Young required by the PCAOB regarding the independent registered public accounting firm’s communications with the Audit Committee concerning independence, and has discussed with Ernst & Young its independence. The Audit Committee has concluded that Ernst & Young’s provision of non-audit services as described in the table above is compatible with Ernst & Young’s independence.

Based on the reviews and discussions referred to above, the Audit Committee recommended to the Board that the audited consolidated financial statements for Danaher for the fiscal year ended December 31, 2024 be included in Danaher’s Annual Report on Form 10-K for the year ended December 31, 2024 for filing with the SEC.

#### Audit Committee of the Board of Directors
<div align='center'>A. Shane Sanders (Chair)

Teri List

John T. Schwieters

Raymond C. Stevens, PhD</div>

| 2025 Notice of Annual Meeting and Proxy Statement |     | 38 |

### Compensation Discussion and Analysis
THE FOLLOWING SECTION DISCUSSES AND ANALYZES THE COMPENSATION PROVIDED TO EACH OF THE EXECUTIVE OFFICERS SET FORTH IN THE 2024 SUMMARY COMPENSATION TABLE ON PAGE 53 , ALSO REFERRED TO AS THE NAMED EXECUTIVE OFFICERS, OR NEOS. THE CONTENT OF THIS COMPENSATION DISCUSSION AND ANALYSIS IS ORGANIZED INTO SIX SECTIONS:

| Table of Contents                                     |     |    |
| Executive Summary                                     |     | 39 |
| Risk Considerations                                   |     | 42 |
| Analysis of 2024 Named Executive Officer Compensation |     | 43 |
| Peer Group Compensation Analysis                      |     | 48 |
| Named Executive Officer Compensation Framework        |     | 49 |
| Other Compensation Policies and Information           |     | 49 |

Executive Summary

### Overview
Following the separation of three of our lines of business over the past decade, 2024 marked Danaher’s first full year as a more strategically focused life sciences and diagnostics